Hepatocellular carcinoma

The Lancet

Volumn 391, Issue 10127, 2018, Pages 1301-1314

  Forner, Alejandro ^a,b   Reig, María ^a,b   Bruix, Jordi ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BRIVANIB; EVEROLIMUS; IODINE 131; LENVATINIB; RAMUCIRUMAB; REGORAFENIB; SEOCALCITIOL; SORAFENIB; TAMOXIFEN; TIVANTINIB; UNCLASSIFIED DRUG; YTTRIUM 90;

ADVANCED CANCER; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CLINICAL RESEARCH; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; ECHOGRAPHY; EVIDENCE BASED MEDICINE; HEPATOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER NODULE; LIVER TRANSPLANTATION; METASTASIS; MILAN CRITERIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TUMOR ABLATION; TUMOR INVASION; LIVER RESECTION; LIVER TUMOR; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 85039957749     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30010-2     Document Type: Review

References (143)

1. IARC. Fact sheets by Population-Globocan-IARC. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed Dec 18, 2016).
2. Forner, A, Llovet, JM, Bruix, J, Hepatocellular carcinoma. Lancet 379 (2012), 1245–1255.
3. El-Serag, HB, Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142, 2012, 1264 73.e1.
4. Chen, CJ, Yang, HI, Su, J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006), 65–73.
5. Chen, JD, Yang, HI, Iloeje, UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 138 (2010), 1747–1754.
6. Morgan, TR, Mandayam, S, Jamal, MM, Alcohol and hepatocellular carcinoma. Gastroenterology 127 (2004), S87–S96.
7. Qiu, D, Katanoda, K, Marugame, T, Sobue, T, A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958–2004). Int J Cancer 124 (2009), 443–448.
8. Bertuccio, P, Turati, F, Carioli, G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 67 (2017), 302–309.
9. Dyson, J, Jaques, B, Chattopadyhay, D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60 (2014), 110–117.
10. Kanwal, F, Kramer, JR, Duan, Z, Yu, X, White, D, El-Serag, HB, Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol, 14, 2016, 301 08.e2.
11. Degasperi, E, Colombo, M, Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 1 (2016), 156–164.
12. Schlesinger, S, Aleksandrova, K, Pischon, T, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 24 (2013), 2449–2455.
13. Tsilidis, KK, Kasimis, JC, Lopez, DS, Ntzani, EE, Ioannidis, JPA, Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ, 350, 2015, g7607.
14. Calle, EE, Rodriguez, C, Walker-Thurmond, K, Thun, MJ, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003), 1625–1638.
15. Marrero, JA, Fontana, RJ, Fu, S, Conjeevaram, HS, Su, GL, Lok, AS, Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42 (2005), 218–224.
16. Bravi, F, Tavani, A, Bosetti, C, Boffetta, P, La Vecchia, C, Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev 26 (2017), 368–377.
17. Ioannou, GN, Bryson, CL, Weiss, NS, Miller, R, Scott, JD, Boyko, EJ, The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 57 (2013), 249–257.
18. Chang, M-H, You, S-L, Chen, C-J, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. Gastroenterology, 151, 2016, 472 80.e1.
19. Papatheodoridis, GV, Chan, HL, Hansen, BE, Janssen, HLA, Lampertico, P, Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 62 (2015), 956–967.
20. Singal, AK, Singh, A, Jaganmohan, S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 8 (2010), 192–199.
21. Morgan, RL, Baack, B, Smith, BD, Yartel, A, Pitasi, M, Falck-Ytter, Y, Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158 (2013), 329–337.
22. Reig, M, Boix, L, Mariño, Z, Torres, F, Forns, X, Bruix, J, Liver cancer emergence associated with antiviral treatment: an immune surveillance failure?. Semin Liver Dis 37 (2017), 109–118.
23. Waziry, R, Hajarizadeh, B, Grebely, J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 67 (2017), 1204–1212.
24. Li, W-Q, Park, Y, McGlynn, KA, et al. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology 60 (2014), 588–597.
25. Chen, H-P, Shieh, J-J, Chang, C-C, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62 (2013), 606–615.
26. Nkontchou, G, Aout, M, Mahmoudi, A, et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila) 5 (2012), 1007–1014.
27. Simon, TG, Bonilla, H, Yan, P, Chung, RT, Butt, AA, Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 64 (2016), 47–57.
28. Schulze, K, Nault, J-C, Villanueva, A, Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol 65 (2016), 1031–1042.
29. Piñol, R, Montal, R, Takayama, T, et al. Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: biomarker study of the STORM phase III trial. J Hepatol, 66, 2017, S12.
30. Sherman, M, Furlan, A, Marin, D, et al. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 28 (2014), 783–793.
31. Croswell, JM, Ransohoff, DF, Kramer, BS, Principles of cancer screening: lessons from history and study design issues. Semin Oncol 37 (2010), 202–215.
32. Zhang, BH, Yang, BH, Tang, ZY, Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 (2004), 417–422.
33. Poustchi, H, Farrell, GC, Strasser, SI, Lee, AU, McCaughan, GW, George, J, Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?. Hepatology 54 (2011), 1998–2004.
34. Singal, AG, Tiro, JA, Marrero, JA, et al. Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma. Gastroenterology, 152, 2017, 608 15.e4.
35. Sarasin, FP, Giostra, E, Hadengue, A, Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 101 (1996), 422–434.
36. Arguedas, MR, Chen, VK, Eloubeidi, MA, Fallon, MB, Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98 (2003), 679–690.
37. Bruix, J, Sherman, M, Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
38. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
39. Lok, AS, Seeff, LB, Morgan, TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136 (2009), 138–148.
40. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
41. Singal, A, Volk, ML, Waljee, A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 30 (2009), 37–47.
42. Singal, AG, Nehra, M, Adams-Huet, B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol 108 (2013), 425–432.
43. Marrero, JA, Feng, Z, Wang, Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137 (2009), 110–118.
44. Lok, AS, Sterling, RK, Everhart, JE, et al. Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138 (2010), 493–502.
45. Zhang, B, Yang, B, Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 6 (1999), 108–110.
46. Capurro, M, Wanless, IR, Sherman, M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125 (2003), 89–97.
47. Shen, Q, Fan, J, Yang, XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 13 (2012), 817–826.
48. Berhane, S, Toyoda, H, Tada, T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol, 14, 2016, 875 86.e6.
49. Santi, V, Trevisani, F, Gramenzi, A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 53 (2010), 291–297.
50. Trinchet, JC, Chaffaut, C, Bourcier, V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 54 (2011), 1987–1997.
51. Forner, A, Vilana, R, Ayuso, C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47 (2008), 97–104.
52. Welch, HG, Black, WC, Overdiagnosis in cancer. J Natl Cancer Inst 102 (2010), 605–613.
53. Sangiovanni, A, Manini, MA, Iavarone, M, et al. The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59 (2010), 638–644.
54. Leoni, S, Piscaglia, F, Golfieri, R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 105 (2010), 599–609.
55. Khalili, KT, Kim, TK, Jang, HJ, et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 54 (2011), 723–728.
56. Rimola, J, Forner, A, Tremosini, S, et al. Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol 56 (2012), 1317–1323.
57. Piana, G, Trinquart, L, Meskine, N, Barrau, V, Van Beers, B, Vilgrain, V, New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 55 (2011), 126–132.
58. American College of Radiology. Liver Imaging Reporting and Data System version. https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/LIRADS/2017/LIRADS_2017_Core.pdf?la=en, 2017 (accessed Nov 27, 2017).
59. Darnell, A, Forner, A, Rimola, J, et al. Liver imaging reporting and data system with MR imaging: evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Radiology 275 (2015), 698–707.
60. Vilana, R, Forner, A, Bianchi, L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51 (2010), 2020–2029.
61. Galassi, M, Iavarone, M, Rossi, S, et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int 33 (2013), 771–779.
62. Tremosini, S, Forner, A, Boix, L, et al. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 61 (2012), 1481–1487.
63. Bruix, J, Reig, M, Sherman, M, Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150 (2016), 835–853.
64. Forner, A, Díaz-González, A, Liccioni, A, Vilana, R, Prognosis prediction and staging. Best Pract Res Clin Gastroenterol 28 (2014), 855–865.
65. Yau, T, Tang, VYF, Yao, T-J, Fan, S-T, Lo, C-M, Poon, RTP, Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology, 146, 2014, 1691 700.e3.
66. Exelixis' phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma. http://www.businesswire.com/news/home/20171016005409/en, Oct 16, 2017 (accessed Nov 30, 2017).
67. Tsochatzis, EA, Bosch, J, Burroughs, AK, Liver cirrhosis. Lancet 17 (2014), 1749–1761.
68. Johnson, PJ, Berhane, S, Kagebayashi, C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 33 (2015), 550–558.
69. Pinato, DJ, Sharma, R, Allara, E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol 66 (2017), 338–346.
70. Llovet, JM, Real, MI, Montana, X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002), 1734–1739.
71. Lo, CM, Ngan, H, Tso, WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002), 1164–1171.
72. Llovet, JM, Bruix, J, Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003), 429–442.
73. Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
74. Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
75. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (in press).
76. Bruix, J, Qin, S, Merle, P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (2017), 56–66.
77. Kalogeridi, M-A, Zygogianni, A, Kyrgias, G, et al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J Hepatol 7 (2015), 101–112.
78. Sangro, B, Carpanese, L, Cianni, R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54 (2011), 868–878.
79. Mazzaferro, V, Sposito, C, Bhoori, S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 57 (2013), 1826–1837.
80. Salem, R, Gordon, AC, Mouli, S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology, 151, 2016, 1155 63.e2.
81. Vilgrain, V, Pereira, H, Assenat, E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 18 (2017), 1624–1636.
82. Chow, P, Gandhi, M, Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus sorafenib in locally advanced hepatocellular carcinoma: the SIRveNIB study. Proc Am Soc Clin Oncol, 35, 2017, 4002 (abstr).
83. Abou-Alfa, G, Niedzwieski, D, Knox, J, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). Proc Am Soc Clin Oncol, 34(suppl 4), 2016, 192 (abstr).
84. Kokudo, N, Hasegawa, K, Akahane, M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res, 2015 published online Jan 27. DOI:10.1111/hepr.12464.
85. Boleslawski, E, Petrovai, G, Truant, S, et al. Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis. Br J Surg 99 (2012), 855–863.
86. Roayaie, S, Jibara, G, Tabrizian, P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62 (2015), 440–451.
87. Llop, E, Berzigotti, A, Reig, M, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 56 (2012), 103–108.
88. Cescon, M, Colecchia, A, Cucchetti, A, et al. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 256 (2012), 706–712.
89. Berzigotti, A, Reig, M, Abraldes, JG, Bosch, J, Bruix, J, Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology 61 (2015), 526–536.
90. Ishizawa, T, Hasegawa, K, Aoki, T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134 (2008), 1908–1916.
91. Shiina, S, Tateishi, R, Arano, T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107 (2012), 569–577.
92. Wang, J-H, Wang, C-C, Hung, C-H, Chen, C-L, Lu, S-N, Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 56 (2012), 412–418.
93. Takayasu, K, Arii, S, Kudo, M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol 56 (2012), 886–892.
94. Burrel, M, Reig, M, Forner, A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 56 (2012), 1330–1335.
95. Malagari, K, Pomoni, M, Moschouris, H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Interv Radiol 35 (2012), 1119–1128.
96. Fuks, D, Dokmak, S, Paradis, V, Diouf, M, Durand, F, Belghiti, J, Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 55 (2012), 132–140.
97. Han, H-S, Shehta, A, Ahn, S, Yoon, Y-S, Cho, JY, Choi, Y, Laparoscopic versus open liver resection for hepatocellular carcinoma: case-matched study with propensity score matching. J Hepatol 63 (2015), 643–650.
98. Hasegawa, K, Kokudo, N, Makuuchi, M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 58 (2013), 724–729.
99. Lu, L-C, Cheng, A-L, Poon, RTP, Recent advances in the prevention of hepatocellular carcinoma recurrence. Semin Liver Dis 34 (2014), 427–434.
100. Lee, JH, Lee, J-H, Lim, Y-S, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 148, 2015, 1383 91.e6.
101. Bruix, J, Takayama, T, Mazzaferro, V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16 (2015), 1344–1354.
102. Ferrer-Fàbrega, J, Forner, A, Liccioni, A, et al. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology 63 (2016), 839–849.
103. Mazzaferro, V, Regalia, E, Doci, R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996), 693–699.
104. Sapisochin, G, Bruix, J, Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 14 (2017), 203–221.
105. Mazzaferro, V, Llovet, JM, Miceli, R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10 (2009), 35–43.
106. Yao, FY, Ferrell, L, Bass, NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33 (2001), 1394–1403.
107. Herrero, JI, Sangro, B, Pardo, F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 14 (2008), 272–278.
108. Duvoux, C, Roudot-Thoraval, F, Decaens, T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 143 (2012), 985–986.
109. Toso, C, Meeberg, G, Hernandez-Alejandro, R, et al. Total tumor volume and α-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 62 (2015), 158–165.
110. Mazzaferro, V, Squaring the circle of selection and allocation in liver transplantation for HCC: an adaptive approach. Hepatology 63 (2016), 1707–1717.
111. Breen, DJ, Lencioni, R, Image-guided ablation of primary liver and renal tumours. Nat Rev Clin Oncol 12 (2015), 175–186.
112. Germani, G, Pleguezuelo, M, Gurusamy, K, Meyer, T, Isgro, G, Burroughs, AK, Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 52 (2010), 380–388.
113. Yu, J, Yu, X, Han, Z, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 66 (2017), 1172–1173.
114. Chen, MS, Li, JQ, Zheng, Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243 (2006), 321–328.
115. Huang, J, Yan, L, Cheng, Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 252 (2010), 903–912.
116. Feng, K, Yan, J, Li, X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 57 (2012), 794–802.
117. Cucchetti, A, Piscaglia, F, Cescon, M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 59 (2013), 300–307.
118. Forner, A, Gilabert, M, Bruix, J, Raoul, J-L, Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11 (2014), 525–535.
119. Varela, M, Real, MI, Burrel, M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46 (2007), 474–481.
120. Lammer, J, Malagari, K, Vogl, T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33 (2010), 41–52.
121. Golfieri, R, Giampalma, E, Renzulli, M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 111 (2014), 255–264.
122. Brown, KT, Do, RK, Gonen, M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34 (2016), 2046–2053.
123. Kudo, M, Han, G, Finn, RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60 (2014), 1697–1707.
124. Lencioni, R, Llovet, JM, Han, G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64 (2016), 1090–1098.
125. Meyer, T, Fox, R, Ma, YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2 (2017), 565–575.
126. Iavarone, M, Cabibbo, G, Piscaglia, F, et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54 (2011), 2055–2063.
127. Reig, M, Rimola, J, Torres, F, et al. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology 58 (2013), 2023–2031.
128. Lencioni, R, Kudo, M, Ye, S-L, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 68 (2014), 609–617.
129. Cheng, AL, Kang, YK, Lin, DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31 (2013), 4067–4075.
130. Johnson, PJ, Qin, S, Park, JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31 (2013), 3517–3524.
131. Zhu, AX, Rosmorduc, O, Evans, TRJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33 (2015), 559–566.
132. Cainap, C, Qin, S, Huang, W-T, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33 (2015), 172–179.
133. Llovet, JM, Peña, CEA, Lathia, CD, Shan, M, Meinhardt, G, Bruix, J, Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18 (2012), 2290–2300.
134. Bruix, J, Cheng, A-L, Meinhardt, G, Nakajima, K, De Sanctis, Y, Llovet, J, Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 67 (2017), 999–1008.
135. Reig, M, Torres, F, Rodriguez-Lope, C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 61 (2014), 318–324.
136. Llovet, JM, Decaens, T, Raoul, JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31 (2013), 3509–3516.
137. Zhu, AX, Kudo, M, Assenat, E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312 (2014), 57–67.
138. Zhu, AX, Park, JO, Ryoo, B-Y, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16 (2015), 859–870.
139. Rimassa, L, Assenat, E, Peck-Radosavljevic, M, et al. Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): results of the METIV-HCC phase III trial. Proc Am Soc Clin Oncol, 35, 2017, 4000 (abstr).
140. Bruix, J, Reig, M, Rimola, J, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 54 (2011), 2238–2244.
141. Lencioni, R, Llovet, JM, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (2010), 52–60.
142. Prieto, J, Melero, I, Sangro, B, Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 12 (2015), 681–700.
143. El-Khoueiry, AB, Sangro, B, Yau, T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 (2017), 2492–2502.